Correlation Between Unicycive Therapeutics and Adaptimmune Therapeutics

Can any of the company-specific risk be diversified away by investing in both Unicycive Therapeutics and Adaptimmune Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Unicycive Therapeutics and Adaptimmune Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Unicycive Therapeutics and Adaptimmune Therapeutics Plc, you can compare the effects of market volatilities on Unicycive Therapeutics and Adaptimmune Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Unicycive Therapeutics with a short position of Adaptimmune Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Unicycive Therapeutics and Adaptimmune Therapeutics.

Diversification Opportunities for Unicycive Therapeutics and Adaptimmune Therapeutics

-0.66

Correlation Coefficient

Unicycive Therapeutics  Adaptimmune Therapeutics

Excellent diversification

The 3 months correlation between Unicycive and Adaptimmune is -0.66. Overlapping area represents the amount of risk that can be diversified away by holding Unicycive Therapeutics and Adaptimmune Therapeutics Plc in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Adaptimmune Therapeutics and Unicycive Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Unicycive Therapeutics are associated (or correlated) with Adaptimmune Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Adaptimmune Therapeutics has no effect on the direction of Unicycive Therapeutics i.e., Unicycive Therapeutics and Adaptimmune Therapeutics go up and down completely randomly.

Pair Corralation between Unicycive Therapeutics and Adaptimmune Therapeutics

Given the investment horizon of 90 days Unicycive Therapeutics is expected to generate 1.22 times more return on investment than Adaptimmune Therapeutics. However, Unicycive Therapeutics is 1.22 times more volatile than Adaptimmune Therapeutics Plc. It trades about 0.23 of its potential returns per unit of risk. Adaptimmune Therapeutics Plc is currently generating about -0.13 per unit of risk. If you would invest  35.00  in Unicycive Therapeutics on September 5, 2024 and sell it today you would earn a total of  36.00  from holding Unicycive Therapeutics or generate 102.86% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Unicycive Therapeutics  vs.  Adaptimmune Therapeutics Plc

Unicycive Therapeutics

Risk-Adjusted Performance

17 of 100

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Unicycive Therapeutics are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak fundamental indicators, Unicycive Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Adaptimmune Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Adaptimmune Therapeutics Plc has generated negative risk-adjusted returns adding no value to investors with long positions. Even with conflicting performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in January 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Pair Trading with Unicycive Therapeutics and Adaptimmune Therapeutics

The main advantage of trading using opposite Unicycive Therapeutics and Adaptimmune Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Unicycive Therapeutics position performs unexpectedly, Adaptimmune Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adaptimmune Therapeutics will offset losses from the drop in Adaptimmune Therapeutics' long position.

The idea behind Unicycive Therapeutics and Adaptimmune Therapeutics Plc pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.